Sublingual and buccal administrations of novel fluorescent films for optical imaging

  • Unmet need: A non-invasive, long-acting continuous release method of administrating fluorescent dyes for precise and continuous disease monitoring
  • The technology: A new bioabsorbable film for sublingual or buccal administration of extended-release fluorescent dyes to be used in optical imaging


Background and Unmet Needs

Fluorescent imaging dyes such as ICG and IRDye® CW800 used for optical imaging are currently administered by deep tissue injection or intravenously and have a short half-life of 3-4 minutes. This can be problematic, as many optical imaging procedures require multiple injections, resulting in a burden for both the patient and clinicians. As such, a novel, continuous release method of administrating these fluorescent dyes would be a significant improvement over the state of the art.


UConn researchers have developed fluorescent films containing imaging agents such as indocyanine green (ICG) and IRDye® CW800 for sublingual or buccal administration for optical imaging. This extended-release film can be used for a wide range of applications including identifying cancerous lymph node metastases, monitoring inflammation, evaluating blood and lymphatic flow and intraoperative cancer disease identification. The extended release allows for continuous monitoring of inflammation and disease states that are unavailable or cumbersome with current fluorescent dye administration technologies. Furthermore, the oral administration of optical imaging dyes allows for swallow evaluation, which is conventionally done using X-Ray fluoroscopy. The use of optical imaging for swallow analysis allows for the avoidance of harmful radiation, which is particularly useful in newborns and infants where it is easy to reach the acceptable maximum radiation before a proper diagnosis can be given.


  • Less invasive administration of fluorescent dyes
  • Increased duration of release to avoid re-administration of the dye
  • Provides continuous monitoring capabilities for tracking of disease progression and more precise diagnosis

Potential Applications

Novel non-invasive, extended-release oral administration of fluorescent dyes such as ICG and IRDye® CW800

Contact Information

Name: Christopher Conners


Phone: 860-679-8772